GH Research (GHRS) Free Cash Flow (2020 - 2025)
GH Research (GHRS) recorded quarterly Free Cash Flow of -$15.5 million in Q4 2025, up 8.76% quarter-over-quarter from -$17.0 million in Q3 2025, and down 22.11% on a YoY basis from -$19.9 million in Q4 2024.
GH Research (GHRS) Free Cash Flow (2020 - 2025) Analysis & Trends
GH Research's Free Cash Flow history runs 6 years deep, the most recent figure standing at -$15.5 million for Q4 2025.
- In Q4 2025, Free Cash Flow fell 22.11% year-over-year to -$15.5 million; the TTM figure through Dec 2025 stood at -$54.9 million (down 12.89% YoY), while the FY2025 annual figure was -$54.9 million, down 12.89% from the prior year.
- Free Cash Flow was -$15.5 million for Q4 2025 at GH Research, up from -$17.0 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$1.1 million in Q1 2021 to a low of -$17.0 million in Q3 2025.
- Historically, Free Cash Flow has averaged -$9.1 million across 5 years, with a median of -$9.6 million in 2021.
- The sharpest annual moves came in 2021 and 2022: Free Cash Flow slumped 11796.1% in 2021, then gained 12.34% in 2022.
- A 5-year view of Free Cash Flow shows it stood at -$4.0 million in 2021, then slumped by 76.52% to -$7.0 million in 2022, then plunged by 44.48% to -$10.1 million in 2023, then fell by 25.94% to -$12.7 million in 2024, then dropped by 22.11% to -$15.5 million in 2025.
- The last three Free Cash Flow figures came in at -$15.5 million (Q4 2025), -$17.0 million (Q3 2025), and -$11.5 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 63,220.27 |
| 10 | GH Research | 9.73 Bn | 9.63 Bn | - | -15.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15.52 Mn |
| Dec 31, 2025 | -15.52 Mn |
| Sep 30, 2025 | -17.01 Mn |
| Sep 30, 2025 | -17.01 Mn |
| Jun 30, 2025 | -11.53 Mn |
| Jun 30, 2025 | -11.53 Mn |
| Mar 31, 2025 | -10.80 Mn |
| Mar 31, 2025 | -10.80 Mn |
| Dec 31, 2024 | -12.71 Mn |
| Dec 31, 2024 | -12.71 Mn |
| Sep 30, 2024 | -13.69 Mn |
| Sep 30, 2024 | -13.69 Mn |
| Jun 30, 2024 | -11.59 Mn |
| Jun 30, 2024 | -11.59 Mn |
| Mar 31, 2024 | -10.60 Mn |
| Mar 31, 2024 | -10.60 Mn |
| Dec 31, 2023 | -10.09 Mn |
| Dec 31, 2023 | -10.09 Mn |
| Sep 30, 2023 | -11.04 Mn |
| Sep 30, 2023 | -11.04 Mn |